• Genetically engineered “ARMORED” tumor infiltrating lymphocytes (TILs) derived (by biopsy or surgical excision) from an individual patient’s tumor specimens
  • Selection for tumor-specific TILs
  • A “personalized” cellular immunotherapy approach
  • No need for co-administration of exogenous IL2, which minimizes side effects
  • Currently being tested in animal models. A Phase 1 clinical trial in patients with metastatic solid tumors is currently being planned.